Terms: = Lung cancer AND KIT, C-Kit, 3815, ENSG00000157404, CD117, SCFR, P10721 AND Treatment
783 results:
1. NPAS2, transcriptionally activated by ARRB1, promotes the malignant behaviours of lung adenocarcinoma cells and regulates the reprogramming of glucose metabolism.
Wang S; Huang C; Zheng Y; Wu X; Zhong Y
Clin Exp Pharmacol Physiol; 2024 May; 51(5):e13860. PubMed ID: 38584327
[TBL] [Abstract] [Full Text] [Related]
2. Babaodan overcomes cisplatin resistance in cholangiocarcinoma via inhibiting YAP1.
Li J; Ma X; Xu F; Yan Y; Chen W
Pharm Biol; 2024 Dec; 62(1):314-325. PubMed ID: 38571483
[TBL] [Abstract] [Full Text] [Related]
3. Polyphyllin I enhances tumor necrosis factor-related apoptosis-inducing ligand-induced inhibition of human osteosarcoma cell growth downregulating the Wnt/β-catenin pathway.
Junli C; Fulai Z; Xingyuan S; Xiaoping MA; Peng Z; Chujie Z; Binhao S; Wenchao GU; Yongjun W; Yanping Y
J Tradit Chin Med; 2024 Apr; 44(2):251-259. PubMed ID: 38504531
[TBL] [Abstract] [Full Text] [Related]
4. Identification of immunological patterns characterizing immune-related psoriasis reactions in oncological patients in therapy with anti-PD-1 checkpoint inhibitors.
Morelli M; Carbone ML; Scaglione GL; Scarponi C; Di Francesco V; Pallotta S; De Galitiis F; Rahimi S; Madonna S; Failla CM; Albanesi C
Front Immunol; 2024; 15():1346687. PubMed ID: 38495872
[TBL] [Abstract] [Full Text] [Related]
5. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell lung cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
Wang L; Xu L; Han S; Zhu X
Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
[TBL] [Abstract] [Full Text] [Related]
6. β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling.
Wang LH; Sun YH; Liu H; Yang X; Wen Z; Tian XF
Chem Biol Drug Des; 2024 Mar; 103(3):e14493. PubMed ID: 38439529
[TBL] [Abstract] [Full Text] [Related]
7. lung-specific exosomes for doxorubicin delivery in lung adenocarcinoma therapy.
Yu F; Chen Y; Yi W; Guan M; Lin N; Zhuo Y; Lin J; Lai F
Biotechnol J; 2024 Feb; 19(2):e2300296. PubMed ID: 38403456
[TBL] [Abstract] [Full Text] [Related]
8. Synthesis and In Vitro Antitumor Activity Evaluation of Gefitinib-1,2,3-Triazole Derivatives.
Liu Z; Liu J; Gao E; Mao L; Hu S; Li S
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398589
[TBL] [Abstract] [Full Text] [Related]
9. Sintilimab with two cycles of chemotherapy for the treatment of advanced squamous non-small cell lung cancer: a phase 2 clinical trial.
Zhang M; Zhang G; Niu Y; Zhang G; Ji Y; Yan X; Zhang X; Wang Q; Jing X; Wang J; Ma Z; Wang H
Nat Commun; 2024 Feb; 15(1):1512. PubMed ID: 38374204
[TBL] [Abstract] [Full Text] [Related]
10. Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.
Tan Q; Gao R; Zhang X; Yang J; Xing P; Yang S; Wang D; Wang G; Wang S; Yao J; Zhang Z; Tang L; Yu X; Han X; Shi Y
Cancer Immunol Immunother; 2024 Feb; 73(3):47. PubMed ID: 38349411
[TBL] [Abstract] [Full Text] [Related]
11. MAP4 acts as an oncogene and prognostic marker and affects radioresistance by mediating epithelial-mesenchymal transition in lung adenocarcinoma.
Xia X; Ge Y; Ge F; Gu P; Liu Y; Li P; Xu P
J Cancer Res Clin Oncol; 2024 Feb; 150(2):88. PubMed ID: 38341398
[TBL] [Abstract] [Full Text] [Related]
12. Cephaeline promotes ferroptosis by targeting NRF2 to exert anti-lung cancer efficacy.
Chen P; Ye Q; Liang S; Zeng L
Pharm Biol; 2024 Dec; 62(1):195-206. PubMed ID: 38339810
[TBL] [Abstract] [Full Text] [Related]
13. R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice.
Chrysostomou SE; Eder S; Pototschnig I; Mayer AL; Derler M; Mussbacher M; Schauer S; Zhang D; Yan D; Liu G; Hoefler G; Weichhart T; Vesely PW; Zhang L; Schweiger M
J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):562-574. PubMed ID: 38302863
[TBL] [Abstract] [Full Text] [Related]
14. SLCO4A1, as a novel prognostic biomarker of non‑small cell lung cancer, promotes cell proliferation and migration.
Li S; Li Z; Huang L; Geng Z; Li F; Wu B; Sheng Y; Xu Y; Li B; Xu Y; Gu Z; Qi Y
Int J Oncol; 2024 Mar; 64(3):. PubMed ID: 38275113
[TBL] [Abstract] [Full Text] [Related]
15. Amplifying T cell-mediated antitumor immune responses in nonsmall cell lung cancer through photodynamic therapy and anti-PD1.
Gong B; Wang L; Zhang H; Wang Q; Li W
Cell Biochem Funct; 2024 Jan; 42(1):e3925. PubMed ID: 38269509
[TBL] [Abstract] [Full Text] [Related]
16. Effects of IFN-γ on the immunological microenvironment and TAM polarity in stage IA non-small cell lung cancer and its mechanisms.
Zhao W; Wang H; Zhang X; Zhang L; Pu W; Ma Y; Chen W
BMC Pulm Med; 2024 Jan; 24(1):46. PubMed ID: 38254043
[TBL] [Abstract] [Full Text] [Related]
17. Triptolide restrains the growth, invasion, stemness, and glycolysis of non-small cell lung cancer cells by PFKFB2-mediated PI3K/AKT pathway.
Ren J; Zhao S; Lai J
Chem Biol Drug Des; 2024 Jan; 103(1):e14450. PubMed ID: 38230789
[TBL] [Abstract] [Full Text] [Related]
18. Combination of the cuproptosis inducer disulfiram and anti‑PD‑L1 abolishes NSCLC resistance by ATP7B to regulate the HIF‑1 signaling pathway.
Li P; Sun Q; Bai S; Wang H; Zhao L
Int J Mol Med; 2024 Feb; 53(2):. PubMed ID: 38186308
[TBL] [Abstract] [Full Text] [Related]
19. Lactate promoted cisplatin resistance in NSCLC by modulating the m6A modification-mediated FOXO3/MAGI1-IT1/miR-664b-3p/IL-6R axis.
Bo W; Yu N; Wang X; Wang C; Liu C
Neoplasia; 2024 Feb; 48():100960. PubMed ID: 38184887
[TBL] [Abstract] [Full Text] [Related]
20. Acute mast cell leukemia without kit D816V mutation and lack of CD2 and CD25-a case report of rare entity.
Zaremba-Pataj E; Patkowska E; Krzywdzińska A; Szumera-Ciećkiewicz A; Chlebowska-Tuz J
J Hematop; 2023 Mar; 16(1):39-47. PubMed ID: 38175371
[TBL] [Abstract] [Full Text] [Related]
[Next]
